BACKGROUND: Novel treatments are needed for the primary and secondary prevention of heart failure in patients with type 2 diabetes, including individuals with and those without a history of heart ...
Zacks Small Cap Research on MSN
CVKD acquires 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia (HIT)
By David Bautz, PhD NASDAQ:CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Acquires 12-LOX Inhibitor VLX-1005 for the Treatment of HIT In December 2025, Cadrenal Therapeutics, Inc.
Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.
Detailed price information for Paradigm Biopharmaceuticl (PBIGF) from The Globe and Mail including charting and trades.
The two proven causes of stomach ulcers are bacteria and painkillers, specifically non-steroidal anti-inflammatory (NSAID) drugs such as aspirin and ibuprofen. Find out why.
With the rapid introduction of novel breast cancer therapies, recognizing and managing side effects is essential to maintain adherence and improve outcomes. As novel oral endocrine therapies and ...
About The Study: This comparative effectiveness study found that initiation of sodium-glucose cotransporter-2 inhibitor (SGLT2i) vs glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in ...
Avenzo Therapeutics Presents Initial Results from the Phase 1/2 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium Avenzo Therapeutics, Inc. ( ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results